Adverum Biotechnologies, Inc. has reported the financial results for the first quarter ended March 31, 2017.
“Adverum is well positioned in the gene therapy space with a robust pipeline and a platform of industry-leading AAV vector technology, including novel vector development capabilities,” said Amber Salzman, Ph.D., president and CEO of Adverum Biotechnologies. “Our strong cash position will help us execute our plans and is expected to fund our three lead gene therapy programs through the end of 2019 to generate meaningful clinical data for at least one of these programs. We are committed to transforming Adverum into a clinical-stage company by the end of this year.”
From the 2017 Outlook:
- For ADVM-053, Adverum’s gene therapy product candidate for treating HAE, the Company met with the FDA in the first quarter of 2017 and is preparing to file an IND.